Nathaniel Brooks Horwitz
Biomedical Venture Capitalist
Biotechnology is ascendant. Recent advances in biology have converged with those in computation, engineering and finance to generate biotech that was once only science fiction.
I study the science, business and ethics of biotech. As CEO of Nivien Therapeutics, I led development of an experimental therapy for pancreatic cancer.
I now serve on the Venture team at RA Capital and on the boards of several portfolio companies as Director or Observer, including Quench Bio, Clear Creek Bio, Eliem Therapeutics, and undisclosed companies.
My writing is published by The Washington Post, NYT, Daily Beast, Boston Globe, The Atlantic and others. My writing does not represent RA Capital.